Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.

Nature immunology·2026
Same author

Autonomic and neural responses to varying transcutaneous cervical electrical stimulation parameters.

Bioelectronic medicine·2026
Same author

Quantitative Lipidomics Reveals Dynamic Lipid Profiles in <i>Cinnamomum camphora</i> Seed Kernels at Different Developmental Stages.

Plants (Basel, Switzerland)·2026
Same author

Segmental specification of the human female fetal reproductive tract revealed by spatiotemporal dynamics.

Nature cell biology·2026
Same author

Ethnic-specific ZJU index thresholds for hepatic steatosis and fibrosis in Chinese MASLD.

Frontiers in medicine·2026
Same author

Detailed single-cell mapping of the transcriptional response to a virus infection driven by copy-back viral genomes.

PLoS pathogens·2026

Related Experiment Video

Updated: Jun 20, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

IL-11 regulates autoimmune demyelination.

Blake T Gurfein1, Yueting Zhang, Carolina B López

  • 1Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|September 8, 2009
PubMed
Summary

Interleukin-11 (IL-11) shows therapeutic potential for multiple sclerosis (MS) by reducing central nervous system (CNS) inflammation and promoting oligodendrocyte survival. This cytokine offers both neuroprotection and immunoregulation for autoimmune demyelinating diseases.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Area of Science:

  • Neuroimmunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Current multiple sclerosis (MS) therapies primarily target inflammation, neglecting neuroprotection and repair.
  • Interleukin-11 (IL-11), a gp130 family cytokine, is found in active MS lesions and influences neural and immune cells.
  • Experimental autoimmune encephalomyelitis (EAE) serves as a model for MS, exhibiting similar clinical and pathological features.

Purpose of the Study:

  • To investigate the role of IL-11 in the clinical course and neuropathology of EAE.
  • To determine if IL-11 exerts neuroprotective and/or immunoregulatory effects in autoimmune demyelination.
  • To explore IL-11 as a potential therapeutic target for MS.

Main Methods:

  • Utilized IL-11 receptor alpha-null (IL-11Rα(-/-)) mice and wild-type littermates to assess EAE severity and neuropathology.
  • Administered IL-11 to wild-type mice during EAE to evaluate its therapeutic effects.
  • Performed co-cultures of T lymphocytes and antigen-presenting cells (APCs) to analyze IL-11's impact on immune responses.
  • Assessed the effects of IL-11 on oligodendrocyte progenitor cell apoptosis and mitosis in vitro.

Main Results:

  • IL-11Rα(-/-) mice exhibited exacerbated EAE severity, increased inflammation, demyelination, and cell loss compared to wild-type controls.
  • IL-11 treatment in wild-type mice significantly reduced clinical signs and neuropathology of EAE.
  • IL-11 decreased T cell-derived effector cytokine production by modulating APC-mediated lymphocyte activation.
  • IL-11 treatment reduced oligodendrocyte progenitor cell apoptosis and promoted mitosis.

Conclusions:

  • IL-11 plays a critical role in regulating the clinical and pathological outcomes of autoimmune demyelinating disease.
  • IL-11 demonstrates a dual mechanism of action, involving both immunoregulation and direct neuroprotection.
  • IL-11 signaling represents a promising therapeutic strategy for restricting CNS inflammation and enhancing oligodendrocyte survival in MS.